GREENWICH BIOSCIENCES
Live / Registered — Registered (as of 18 Nov 2025)
What this means for you
Registered since 18 Nov 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99058243
- Registration number
- 8028682
- Mark type
- Stylized text
- Filed
- 26 Feb 2025
- Published for opposition
- 30 Sept 2025
- Registered
- 18 Nov 2025
- Attorney of record
- Michael T. Olsen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of pain, neuropathic pain, cancer pain, perioperative pain, cancer symptoms, multiple sclerosis (MS), spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC), generalised epilepsy with febrile seizures plus (GEFS positive), dup 15, and Doose syndrome, and for use in oncology; pharmaceutical preparations and substances for the treatment of bladder dysfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, LennoxGastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis; pharmaceutical preparations and substances for the treatment of metabolic disorders, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness and for the use in oncology; pharmaceutical preparations and substances for the treatment of diabetes, type II diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism; herbs for medicinal purposes; medicinal herbs; medicinal infusions for treating pain, neuropathic pain, cancer pain, peri-operative pain, cancer symptoms, multiple sclerosis, spasticity, MS spasticity, convulsions, seizures, epilepsy, paediatric epilepsy, intractable childhood epilepsy with generalized tonic-clonic seizures (ICEGTC), generalised epilepsy with febrile seizures plus (GEFS positive), dup 15, and Doose syndrome and for use in oncology; medicinal infusions for treating bladder dysfunction, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Alzheimer's, Dravet syndrome, LennoxGastaut syndrome (LGS), spinal cord injury, head injury, bone disorders, chromosome disorders, inflammatory disorders, inflammation, arthritis; medicinal infusions for treating metabolic disorders, cancer symptoms, neurodegenerative diseases, diseases of the central nervous system, peripheral neuropathy, neurogenic symptoms, hypoxicischemic encephalopathy, neonatal hypoxic encephalopathy, stroke, motion sickness and chemically induced sickness and for use in oncology; medicinal infusions for treating diabetes, type II diabetes, obesity, obesity associated with diabetes, bulimia, psychiatric disorders, schizophrenia, and drug, alcohol and nicotine abuse, autism; pure extracts of medicinal plants and herbs other than essential oils for medical, veterinary and pharmaceutical purposes; foodstuffs for medicinal purposes, namely, medicated supplements for foodstuffs for babies and animals; herb teas for medicinal purposes
Owner
- Jazz Pharmaceuticals Operations UK Limited, Kent, GB
- Jazz Pharmaceuticals Operations UK Limited, Kent, GB
- Jazz Pharmaceuticals Operations UK Limited, Kent, GB
Prior registrations
Prosecution history
- 18 Nov 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 18 Nov 2025 — REGISTERED-PRINCIPAL REGISTER
- 30 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Sept 2025 — PUBLISHED FOR OPPOSITION
- 24 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Aug 2025 — NON-FINAL ACTION E-MAILED
- 08 Aug 2025 — NON-FINAL ACTION WRITTEN
- 31 Jul 2025 — ASSIGNED TO EXAMINER
- 26 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 26 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED